Navigation Links
Evaluating That Thing On Your Skin Just Got a Whole Lot Easier
Date:11/5/2013

BOSTON, Nov. 5, 2013 /PRNewswire/ -- Olay® facial cream's famous motto was "Love the skin you're in." We should, since our largest organ does so much for us. Skin acts as a waterproof insulating shield, guarding the body against extremes of temperature, damaging sunlight and harmful chemicals. It exudes antibacterial substances that prevent infection, and manufactures vitamin D for converting calcium into healthy bones. Skin is also a huge sensor, packed with nerves for keeping the brain in touch with the outside world. But loving the skin we're in is actually easier said than done, because of the ever-present possibility of skin cancer. 

This is an understandable concern, with the American Cancer Society reporting there are more than 3.5 million skin cancers diagnosed each year—more than all other cancers combined. This makes us leery of every suspicious lump, mole, skin tag or discoloration on the body. We also worry that our doctor might overlook a potentially cancerous lesion; or if not, that the biopsy will be painful and leave us with a visible scar. Scarring does happen, even if that suspicious lesion is benign.

Is there an answer to this all-too-prevalent dilemma?

Now there is, thanks to a remarkable advance in medical instrumentation. Based in Boston and Rochester, Caliber Imaging & Diagnostics (Caliber I.D.) is a leader in noninvasive optical biopsies—i.e., its technology can capture high-resolution images providing doctors with cellular views at varying depths under the skin, enabling an accurate real-time diagnosis. Caliber I.D. has created and is already marketing a suite of its FDA-cleared devices, known as VivaScope® confocal imaging systems.

Since there is no cutting involved with VivaScope, there is also no possibility of infection or scarring. Obtaining an
'/>"/>

SOURCE Caliber I.D.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinsons Disease
2. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
3. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
4. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
5. Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
6. Study Showcases Effective Approaches for Evaluating the Performance of Executives who Handle Managed Markets Accounts
7. Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer
8. NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinsons Disease
9. Arena Pharmaceuticals Completes Phase 1b Clinical Trial Evaluating APD811 for Pulmonary Arterial Hypertension
10. AtheroMed Announces Completion of Patient Enrollment in the EASE Study Evaluating the Phoenix Atherectomy System in Treating PAD
11. AtheroMed Announces Results Of The EASE Study Evaluating The Phoenix Atherectomy System In Treating Peripheral Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/nk3569/future_horizons ... "Future Horizons and Growth Strategies in the European ... Forecasts" report to their offering. ... Blood Banking Market 2015 is a new five-countrystrategic ... and potential market entrants identify and evaluate emerging ...
(Date:7/1/2015)... , July 1, 2015 Rock Creek Pharmaceuticals, ... focused on chronic inflammatory disease and neurologic disorders, announced ... study with anatabine citrate, the Company,s lead compound. Results ... of anatabine citrate can significantly inhibit the activation of ... Company is developing this compound in a Phase 1 ...
(Date:7/1/2015)... , July 1, 2015  BioPharmX Corporation (NYSE MKT: ... underwritten public offering of 3,636,364 shares of its common ... per share. BioPharmX has granted the underwriters a 30-day ... common stock at the public offering price. ... an existing stockholder, has agreed to purchase 1,081,081 shares ...
Breaking Medicine Technology:European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 2European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 4BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 2BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 3
... 12 CVS Caremark Corporation (NYSE: CVS ) today announced ... of approximately 15%, to 8.75 cents per share on the Common ... record on January 22, 2010 . This increase translates into an annual ... per share from the previous rate of 30.5 cents . , ...
... , ST. JOSEPH, Mich. , Jan. 12 ... announced today they have been awarded a $336K Phase I ... for creating a novel type of predictive signatures for drug ... should overcome many shortcomings of existing methods of molecular diagnostics. ...
Cached Medicine Technology:CVS Caremark Corporation Increases Quarterly Dividend 15% 2GeneGo Receives SBIR Grant 2GeneGo Receives SBIR Grant 3
(Date:7/1/2015)... ... July 01, 2015 , ... ... of Levaquin ( http://www.injurybeacon.com/levaquin/lawsuit/ ) has granted the Defendants’ Motion for Summary Judgment. ... West Virginia on June 26th, the Court rejected the Plaintiff’s assertion that ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... today announced that they will welcome four new members to their industry leading ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... natural forms, such as organically raised chickens and eggs. Eating organic foods and ... chickens is cleaner and more environmentally friendly than production chicken farming. Choosing home ...
(Date:7/1/2015)... York, NY (PRWEB) , ... July 01, 2015 , ... ... $100,000 from the New York Community Trust. The grant will allow CCF to improve ... sharing proven practices. , CCF was formed to respond to many changes in New ...
(Date:7/1/2015)... NY (PRWEB) , ... July 01, 2015 , ... Summer ... taboo with teenagers to fix noses and chins with plastic surgery when they’re looking ... Surgeons (ASPS) more than 236,000 cosmetic procedures were performed on patients ages 19 and ...
Breaking Medicine News(10 mins):Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:Chicken Coop Condo Offer New Chicken Coop Designs 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3Health News:Top Manhattan Facial Plastic Surgeon Dr. Sam Rizk Comments on Teen Surgery Trends 2Health News:Top Manhattan Facial Plastic Surgeon Dr. Sam Rizk Comments on Teen Surgery Trends 3
... The Breast, Cancer Patient Protection Act, Championed by ... DeLauro (D-CT) and Moran (R-KS) -, - Effort Part ... Campaign to Encourage Women to Speak Out on Issues That ... a Capitol Hill,press conference, actress Marcia Cross joined Lifetime and ...
... reward center, which can go awry , , WEDNESDAY, Jan. ... specific part of the brain handles what might be ... could lead scientists closer to more effective treatments for ... a brain region is helpful because it provides insight ...
... that field mice have evolved a unique way of ensuring ... infertility in humans. , The team, in collaboration with ... their immunity protection in favour of a more rapid fertilisation ... protein, called CD46. Present in both animals and humans, ...
... week cut death risk in half, study found , , WEDNESDAY, ... of exercise can dramatically prolong a man,s life, new research ... analysis -- the largest such study ever -- found that ... least four to six days a week was enough to ...
... KIRKLAND, Wash., Jan. 23 "A failing mind, ... care today," says Cameron,Truesdell, CEO of LTC Financial Partners, ... shouldn,t be, so we,re going to give,our clients information ... is offering a free guidebook and web links to ...
... Label Highlights CLARITIN Effectively Treats Indoor and ... Schering-Plough,(NYSE: SGP ) today announced ... has,approved additional labeling for CLARITIN(R) (loratadine), which ... relieves,allergy symptoms caused by both indoor (also ...
Cached Medicine News:Health News:Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross and Lifetime Television Deliver 20 Million Online Petition Signatures to Capitol Hill to Urge Congress to Stop 'Drive-Through' Mastectomies 2Health News:Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross and Lifetime Television Deliver 20 Million Online Petition Signatures to Capitol Hill to Urge Congress to Stop 'Drive-Through' Mastectomies 3Health News:Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross and Lifetime Television Deliver 20 Million Online Petition Signatures to Capitol Hill to Urge Congress to Stop 'Drive-Through' Mastectomies 4Health News:Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross and Lifetime Television Deliver 20 Million Online Petition Signatures to Capitol Hill to Urge Congress to Stop 'Drive-Through' Mastectomies 5Health News:Specific Brain Region Governs Problem-Solving Skills 2Health News:Specific Brain Region Governs Problem-Solving Skills 3Health News:Evolutionary phenomenon in mice may explain human infertility 2Health News:A Little Regular Exercise Extends Men's Lives 2Health News:A Little Regular Exercise Extends Men's Lives 3Health News:Long Term Care Insurance Leader Offers Advice on Preventing Dementia, the Leading Cause of Care Claims 2Health News:FDA Approves Labeling Change for Non-Drowsy CLARITIN(R) 2Health News:FDA Approves Labeling Change for Non-Drowsy CLARITIN(R) 3
2.5 mm x 0.6 mm. Overall length: 122 mm, 4.8 inches....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Massive retinal breaks. Inner diameter: 26 mm....
Concave inner surface to conform to the globe. Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Wide scleral bed. Outside diameter 30.2 mm....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
Medicine Products: